PharmaCyte Biotech Net Income

The latest net income for PMCB is $-17M as of July 2026. That compares with $-1.1M in the prior-year period — down 1423.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside PharmaCyte Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, PMCB's net income moved from $-1.1M to $-17M — a 1423.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PharmaCyte Biotech's operating scale or balance-sheet position.

Against Healthcare companies, PMCB currently prints $-17M for net income, while the sector average sits near $16B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at PharmaCyte Biotech's growth, margins, and balance sheet.

A net income figure of $-17M for PMCB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting PMCB's net income ($-17M), review year-over-year change from $-1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.